
MoonLake Immunotherapeutics (MLTX)
Order type
Buy in
Order amount
Est. shares
0 shares
Buy MoonLake Immunotherapeutics (MLTX) Stock
Start investing in MoonLake Immunotherapeutics (MLTX)
About MoonLake Immunotherapeutics (MLTX)
Market cap | $2.81B |
Today's volume | 1 |
Revenue (TTM) | — |
Avg. daily volume | 536.1K |
EBITDA (TTM) | -$169.02M |
Open | $43.36 |
Price / earnings ratio | -19.19x |
Today's range | $42.97 - $44.43 |
Debt / equity | 18.55x |
52 week range | $31.42 - $58.26 |
5 year debt / equity | 0.22x |
Beta (LTM) | 0.87x |
Interest coverage | — |
Dividend & yield | $0.00 (0.00%) |
Current ratio | 21.11x |
Ex-dividend date | — |
Next earnings | Aug 6, 2025 |
Dividend payable date | — |
MoonLake Immunotherapeutics Stock Rating
MoonLake Immunotherapeutics Stock News
View all



Frequently Asked Questions (FAQ)
How to buy MLTX stock on Public
- 1
Sign up for a brokerage account on Public
It’s easy to get started. You can sign up for an account directly on our website or by downloading the Public app for iOS or Android.
- 2
Add funds to your Public account
There are multiple ways to fund your Public account—from linking a bank account to making a deposit with a debit card or wire transfer.
- 3
Choose how much you'd like to invest in MLTX stock
Navigate to the Explore page. Then, type MLTX into the search bar. When you see MLTX stock appear in the results, tap it to open up the purchase screen.
- 4
Manage your investments in one place
You can find your newly purchased MLTX stock in your portfolio—alongside the rest of your stocks, ETFs, crypto, treasuries, and alternative assets.
MoonLake Immunotherapeutics Stock Earnings
The value each MLTX share was expected to gain vs. the value that each MLTX share actually gained.
MoonLake Immunotherapeutics (MLTX) reported Q1 2025 earnings per share (EPS) of -$0.63, beating estimates of -$0.75 by 16.00%. In the same quarter last year, MoonLake Immunotherapeutics's earnings per share (EPS) was -$0.22. MoonLake Immunotherapeutics is expected to release next earnings on 08/06/2025, with an earnings per share (EPS) estimate of $0.